Home › Fabry Disease
Fabry Disease clinical trials recruiting in the U.S.
11 studies for Fabry Disease are recruiting participants at sites across the United States.
Cities with the most studies
- Atlanta, GA7 studies
- Arlington, VA6 studies
- Birmingham, AL5 studies
- Minneapolis, MN5 studies
- Cincinnati, OH4 studies
- Pittsburgh, PA4 studies
- Chicago, IL4 studies
- Salt Lake City, UT3 studies
- Cedar Rapids, IA3 studies
- Dallas, TX3 studies
- New York City, NY3 studies
- Philadelphia, PA3 studies
By state
- Alabama5 studies
- California3 studies
- Georgia7 studies
- Illinois4 studies
- Iowa3 studies
- Minnesota5 studies
- New York4 studies
- Ohio4 studies
- Pennsylvania6 studies
- Texas3 studies
- Utah3 studies
- Virginia6 studies
Recently updated studies
Maternal and Postnatal Outcomes Study (MOS): A Global Observational Registry Assessing the Safety of Elfabrio® in Women With Fabry Disease and Their Infants During Pregnancy and Breastfeeding
RecruitingObservational study
All ages · Women · Updated Nov 13, 2026 · NCT06941025A Study to Learn How Well Lucerastat Works and How Safe it is in Untreated Adult Male Participants With Fabry Disease
RecruitingPhase 3
Ages 18 to 60 · Men · Updated Nov 3, 2026 · NCT07778667A Study of Patients With Fabry Disease (US Specific)
RecruitingObservational study
Ages 18 and older · All sexes · Updated Oct 28, 2026 · NCT06906367A Global Prospective Observational Study of Women With Fabry Disease and Their Infants During Pregnancy and Breastfeeding
RecruitingObservational study
All ages · Women · Updated Oct 28, 2026 · NCT04252066A Study of Migalastat in Pediatric Subjects (2 to <12 Yrs) With Fabry Disease and Amenable GLA Variants
RecruitingPhase 3
Ages 2 to 11 · All sexes · Updated Oct 22, 2026 · NCT06904261Fabry Disease Registry & Pregnancy Sub-registry
RecruitingObservational study
All ages · All sexes · Updated Oct 14, 2026 · NCT00196742Safety, PK/PD, and Exploratory Efficacy Study of AMT-191 in Classic Fabry Disease
RecruitingPhase 1/2
Ages 18 to 65 · Men · Updated Sep 24, 2026 · NCT06270316Natural History and Structural Functional Relationships in Fabry Renal Disease Treatment Outcomes(Changes)in Fabry Renal Disease Study
RecruitingObservational study
Ages 1 to 75 · All sexes · Updated Aug 14, 2026 · NCT01581424A Study to Learn About the Safety and Effects of the Study Drug PRX-102 in Children and Adolescents With Fabry Disease
RecruitingPhase 2/3
Ages 2 to 17 · All sexes · Updated Aug 10, 2026 · NCT06328608Cardiovascular Multimodality Imaging Study
RecruitingObservational study
Ages 18 and older · All sexes · Updated Aug 10, 2026 · NCT06610019A Multi-Country Observational Study of Safety and Effectiveness of Elfabrio® in Fabry Patients
RecruitingObservational study
Ages 18 and older · All sexes · Updated Nov 14, 2025 · NCT06663358From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.